Status:
COMPLETED
A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma
Lead Sponsor:
Mayo Clinic
Conditions:
Multiple Myeloma
Eligibility:
All Genders
Brief Summary
This study evaluates the outcomes of patients undergoing initial therapy for multiple myeloma.
Detailed Description
PRIMARY OBJECTIVE: I. Compare the overall survival between bortezomib, lenalidomide and dexamethasone (VRd), daratumumab, lenalidomide and dexamethasone (DRd) and daratumumab, bortezomib, lenalidomid...
Eligibility Criteria
Inclusion
- Previously untreated active multiple myeloma starting a new treatment for the disease with one of the three established treatment regimens: VRd (bortezomib, lenalidomide, dexamethasone), DRd (daratumumab lenalidomide dexamethasone), or DVRd (daratumumab, bortezomib, lenalidomide, and dexamethasone)
- No prior treatment for myeloma
- Not receiving concurrent treatment for another active malignancy
- No more than 3 months from start of treatment
Exclusion
- Does not meet all inclusion criteria
Key Trial Info
Start Date :
September 21 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 5 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06151717
Start Date
September 21 2023
End Date
June 5 2025
Last Update
June 17 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259
2
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224-9980
3
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
4
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, United States, 54601